- Home
- ATRA
as of 01-16-2026 3:40pm EST
$4.55
$0.07
-1.52%
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 129.4M | IPO Year: | 2014 |
| Target Price: | $6.00 | AVG Volume (30 days): | 610.3K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.25 - $19.14 | Next Earning Date: | 03-06-2026 |
| Revenue: | $151,930,000 | Revenue Growth: | 51.27% |
| Revenue Growth (this year): | -4.09% | Revenue Growth (next year): | -52.21% |
AI-Powered ATRA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Atara Biotherapeutics Inc. (ATRA)
Panacea Innovation Ltd
Sell
10% Owner
ATRA Jan 12, 2026
Avg Cost/Share
$6.07
Shares
80,554
Total Value
$489,019.17
Owned After
1,324,446
SEC Form 4
Nguyen AnhCo
Sell
President and CEO
ATRA Nov 17, 2025
Avg Cost/Share
$13.19
Shares
2,915
Total Value
$38,437.30
Owned After
65,030
Grant-Huerta Yanina
Sell
Chief Accounting Officer
ATRA Nov 17, 2025
Avg Cost/Share
$13.19
Shares
1,804
Total Value
$23,788.08
Owned After
33,613
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | ATRA | 10% Owner | Jan 12, 2026 | Sell | $6.07 | 80,554 | $489,019.17 | 1,324,446 | |
| Nguyen AnhCo | ATRA | President and CEO | Nov 17, 2025 | Sell | $13.19 | 2,915 | $38,437.30 | 65,030 | |
| Grant-Huerta Yanina | ATRA | Chief Accounting Officer | Nov 17, 2025 | Sell | $13.19 | 1,804 | $23,788.08 | 33,613 |
Latest Atara Biotherapeutics Inc. News
ATRA Breaking Stock News: Dive into ATRA Ticker-Specific Updates for Smart Investing
MT Newswires
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold From Buy, Adjusts PT to $6 From $25
📊
AI Sentiment
Positive
7/10
Business Wire
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
📉
AI Sentiment
Negative
3/10
BioPharma Dive
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
📊
AI Sentiment
Positive
7/10
Compare ATRA vs Leading Stocks
See how ATRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ATRA Atara Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.